Trial Profile
Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRANSIT-1
- Sponsors Actelion Pharmaceuticals
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 07 Nov 2016 According to Actelion Pharmaceuticals media release, this study is expected to be completed before the end of 2016.